Closely-held CSA Medical announced publication of a research letter in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), which highlights the initial safety data of the company’s RejuvenAir System.
The data supports the safety of using Liquid Nitrogen Metered Cryospray (MCS) in the lobar and first segmental airways of the human bronchial system.
The data set encompasses 16 patients with peripheral lung nodule resection in two separate studies. In total, 32 MCS were successfully delivered without device-related adverse events in these distal airways, which supports the safety of delivering Liquid Nitrogen MCS with the RejuvenAir System.
The results of these two initial studies led to the initiation of a clinical trial investigating the safety and feasibility of delivering Liquid Nitrogen MCS therapy in chronic bronchitis patients.
CSA is developing an interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing.
